抑制BUB1使TNBC细胞系对化疗和放射治疗产生敏感性
Sushmitha Sriramulu1, Shivani Thoidingjam1, Farzan Siddiqui1,2,3
1Department of Radiation Oncology, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI 48202, USA.
Biomolecules
|June 27, 2024
概括
抑制BUB1激酶使三阴性乳腺癌 (TNBC) 细胞对化疗和辐射敏感. 这种BUB1抑制剂,BAY1816032,在改善TNBC治疗疗效方面显示出有前途,无论BRCA状态如何.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 在固体癌症中,BUB1过度表达,与预后不佳相关,特别是在三阴性乳腺癌 (TNBC) 中.
- TNBC经常表现出对标准化疗和放射治疗的耐药性.
- 之前的研究表明,BUB1抑制可以减少TNBC的增殖,并增强放射治疗.
研究的目的:
- 评估BUB1抑制剂BAY1816032与其他药物结合使用以及在TNBC中进行放射治疗的有效性.
- 为了确定BUB1抑制是否使TNBC细胞对PARP抑制剂,剂和微管毒素敏感,有或没有辐射.
主要方法:
- 使用了细胞毒性和克隆基因生存测试.
- 评估的BAY1816032与olaparib (PARP抑制剂),cisplatin (剂) 和paclitaxel (微管毒素) 结合使用.
- 在BRCA1/2野生型和突变TNBC细胞系中,评估了带有和没有放射治疗的组合.
主要成果:
- BAY1816032 协同使BRCA1/2野生型TNBC细胞对olaparib,cisplatin和paclitaxel产生敏感.
- 在无毒度下,BUB1抑制剂增强了这些药物对TNBC细胞的放射敏感性.
- BAY1816032协同使BRCA突变TNBC细胞对olaparib敏感,并显著增加了辐射增强.
结论:
- 不管BRCA1/2突变状态如何,BUB1激酶抑制使TNBC细胞系对PARP抑制剂和辐射敏感.
- BAY1816032证明了作为TNBC的化学敏感剂和放射敏感剂的潜力.
- 这项研究支持BUB1作为一种新的分子标,以提高TNBC中的化学辐射疗效.
关键词:
BAY181603232 的时间.一个BUB1一个BUB1在PARP中,PARP是PARP.美国TNBC电视台化学辐射的发生.西斯普拉丁 (cisplatin) 是一种制剂.这就是Olaparib.帕克利塔克塞尔 (paclitaxel) 是一种药物.辐射辐射辐射辐射的辐射更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.3K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K